- Conditions
- Oncology, MET Gene Amplification, NSCLC, MET Gene Mutation, Non Small Cell Lung Cancer
- Interventions
- Sym015
- Drug
- Lead sponsor
- Symphogen A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Chicago, Illinois • Indianapolis, Indiana + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 1,392
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- decitabine
- Drug
- Lead sponsor
- California Cancer Consortium
- Network
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 4
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California
- Conditions
- Lymphoma
- Interventions
- apolizumab
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Batoclimab 680 mg SC weekly, Batoclimab 340 mg SC weekly, Matching Placebo SC, Batoclimab 340 mg SC bi-weekly
- Drug
- Lead sponsor
- Immunovant Sciences GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Carlsbad, California + 27 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Secukinumab, Adalimumab
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 853 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 19
- States / cities
- Fountain Valley, California • Fullerton, California • La Mesa, California + 16 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg), IMC-A12 (cixutumumab) - 20 mg/kg, Sorafenib
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Chicago, Illinois + 4 more
- Conditions
- HIV Infections
- Interventions
- GSK3810109A, Dolutegravir+lamivudine SOC regimen
- Biological
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 7
- States / cities
- Long Beach, California • Los Angeles, California • Orlando, Florida + 3 more
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Modesto, California • Westminster, California + 13 more
- Conditions
- CLL, SLL, CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Treatment Free Observation
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Monroe, North Carolina • Philadelphia, Pennsylvania
- Conditions
- Multiple Myeloma
- Interventions
- IGM-2644
- Drug
- Lead sponsor
- IGM Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 5
- States / cities
- Duarte, California • Denver, Colorado • New York, New York + 2 more
- Conditions
- Community-acquired Pneumonia, Bacterial Pneumonia
- Interventions
- CMTX-101, Placebo
- Drug
- Lead sponsor
- Clarametyx Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 8
- States / cities
- Augusta, Georgia • Idaho Falls, Idaho • Louisville, Kentucky + 5 more
- Conditions
- Systemic Sclerosis, Scleroderma
- Interventions
- Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2003
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Boston, Massachusetts • New Brunswick, New Jersey + 1 more
- Conditions
- Adalimumab
- Interventions
- ABP 501-HCF, ABP 501-LCF
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 372 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 3
- States / cities
- Cypress, California • South Miami, Florida • Salt Lake City, Utah
- Conditions
- Multiple Myeloma, Myeloma, Smoldering Multiple Myeloma
- Interventions
- (Anti-KIR)
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HIV Antibodies
- Interventions
- VRC-HIVMAB091-00-AB, rHuPH20
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pancreatic Cancer
- Interventions
- MVT-5873, modified FOLFIRINOX (mFOLFIRINOX), gemcitabine + nab-paclitaxel
- Drug
- Lead sponsor
- BioNTech Research & Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Sarasota, Florida + 2 more
- Conditions
- Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
- Interventions
- Elotuzumab, Questionnaire Administration
- Biological · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Crohn's Disease, Inflammatory Bowel Disease
- Interventions
- AIN457
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 5
- States / cities
- Bristol, Connecticut • Great Neck, New York • New York, New York + 2 more
- Conditions
- Cutaneous T-Cell Lymphoma
- Interventions
- HuMax-CD4
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 2
- States / cities
- Stanford, California • Houston, Texas
- Conditions
- Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
- Interventions
- Not listed
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 6
- States / cities
- Orange, California • San Francisco, California • Miami, Florida + 3 more
- Conditions
- Neuroblastoma
- Interventions
- beta-glucan, monoclonal antibody 3F8, immunohistochemistry staining method, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 0 Years to 120 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV
- Interventions
- MVA-CMDR
- Biological
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years to 62 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Staphylococcal Sepsis
- Interventions
- Pagibaximab (formerly BSYX-A110)
- Drug
- Lead sponsor
- Biosynexus Incorporated
- Industry
- Eligibility
- 48 Hours to 120 Hours
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Relapsed Refractory Multiple Myeloma (RRMM)
- Interventions
- Linvoseltamab, Elotuzumab, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Gainesville, Florida • Lexington, Kentucky + 7 more